PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Empagliflozin - Chronic Kidney Disease
PAD Profile : Empagliflozin - Chronic Kidney Disease Important
Keywords :
CKD
Brand Names Include :
Jardiance
Important Information :
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to Empagliflozin initiation.
Traffic Light Status
Status 1 of 1.
Status :
Green
Formulations :
- Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Type
Document
Review Date
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
06 March 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves empagliflozin as a treatment option for treating chronic kidney disease in line with NICE TA942.
NB: Check NICE guidance for recommended patient cohorts regarding eGFR.
Empagliflozin will be considered GREEN on the traffic light system.
Key considerations:
- If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist diabetes team may be prudent prior to empagliflozin initiation.
Associated BNF Codes
06. Endocrine System
06.01.02. Antidiabetic drugs